Product image of Montelukast Lek-Am (Montelukast) supplied by GNH India

Montelukast Lek-Am

Active Ingredient:
Montelukast
Origin:
EU

Montelukast Lek-Am (Montelukast)

Montelukast, the active ingredient in Montelukast Lek-Am, is a leukotriene receptor antagonist presented as a tablet for oral use. It is used to manage asthma and allergic rhinitis in both adult and pediatric patients requiring maintenance therapy. It also helps reduce the frequency of asthma attacks and improves overall respiratory function.

GNH India supplies Montelukast Lek-Am as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet the needs of healthcare providers.

Manufacturer / TM Owner

Przedsiębiorstwo Farmaceutyczne Lek-Am Sp. Z O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Montelukast is indicated for conditions involving leukotriene‑mediated inflammation, primarily within the respiratory tract.

  • Asthma: maintenance therapy to control symptoms and reduce exacerbations.
  • Allergic rhinitis: relief of nasal congestion, sneezing and itching.
  • Exercise‑induced bronchoconstriction: prevention of airway narrowing during physical activity.

How It Works

  • Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1. By antagonizing this receptor, it prevents leukotriene D4 from binding, which inhibits bronchoconstriction, mucus secretion, vascular permeability and eosinophilic inflammation in the airways. This action reduces airway hyper‑responsiveness and improves breathing in patients with asthma and allergic rhinitis. The oral formulation allows systemic distribution, achieving effective receptor occupancy throughout the respiratory tract.

Side Effects

Montelukast may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

  • Headache
  • Abdominal pain
  • Cough
  • Sore throat
  • Nausea
  • Diarrhea

Serious or Rare Side Effects

  • Allergic reactions (rash, angioedema)
  • Mood changes (depression, suicidal thoughts)
  • Liver enzyme elevation
  • Severe skin reactions (Stevens‑Johnson syndrome)
  • Eosinophilic granulomatosis with polyangiitis
  • Anaphylaxis

Precautions & Warnings

When prescribing Montelukast, clinicians should consider several safety measures.

  • Assess liver function: monitor hepatic enzymes in patients with pre‑existing liver disease.
  • Avoid use in patients with known hypersensitivity to montelukast or any tablet excipients.
  • Caution in patients with a history of psychiatric disorders: monitor for mood changes.
  • Consider dose adjustment in severe renal impairment: follow prescriber guidance.
  • Pregnancy and lactation: risk unknown, use only if clearly needed.
  • Store at ambient temperature: keep in original container, protect from moisture and heat.

Avoid Interactions

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Phenobarbital: may reduce montelukast plasma levels.
  • Rifampin: induces metabolism, decreasing efficacy.
  • Ketoconazole: may increase montelukast exposure.

Moderate Interactions (Monitor Closely)

  • Warfarin: possible alteration of anticoagulant effect.
  • Beta‑agonists: additive bronchodilation effect.
  • Corticosteroids: may enhance anti‑inflammatory response.

Frequently Asked Questions

Montelukast Lek-Am is used as a maintenance therapy for asthma, to relieve symptoms of allergic rhinitis such as nasal congestion and sneezing, and to prevent exercise‑induced bronchoconstriction. It works by targeting leukotriene pathways that contribute to airway inflammation and narrowing.

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition stops the cascade that leads to bronchoconstriction, mucus production, and inflammation in the airways, thereby improving breathing and reducing allergic symptoms.

The appropriate dose of Montelukast Lek-Am is determined by the prescribing healthcare professional based on the patient’s age, condition, and clinical response. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

The safety of Montelukast in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Montelukast Lek-Am product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids and long‑acting beta‑agonists. While inhaled steroids target a broader range of inflammatory pathways, Montelukast is particularly useful for patients with aspirin‑sensitive asthma or those who prefer a once‑daily oral tablet.

Montelukast Lek-Am tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and excessive heat. Keep the container tightly closed and out of reach of children.

Montelukast Lek-Am is taken orally as a tablet. The tablet should be swallowed whole with water, preferably in the evening, unless otherwise directed by a healthcare professional.

Serious risks include mood changes such as depression or suicidal thoughts, severe allergic reactions (rash, angioedema), liver enzyme elevations, and rare but severe skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast should not be used by individuals with known hypersensitivity to montelukast or any of the tablet’s excipients. Caution is also advised for patients with severe hepatic impairment, active psychiatric disorders, or those who are pregnant or breastfeeding without clear medical justification.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Montelukast

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT